Perspective · 29 Sep 2022
Conference abstractPublished 26 Oct 2015
U.S. biosimilars – The courts interpret BCPIA steps
Sunstein Kann Murphy & Timbers LLP, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
SANDOZ filed an aBLA seeking the first approval of a U.S. biosimilar, a filgrastim product. AMGENâÂ?Â?s NeupogenÃ?® was the reference product. U.S. biosimilar companies closely followed progress of the first product to use the U.S. Biosimilar law (Biologics Price Control and Innovation Act. Surprisingly, SANDOZ did not proceed through the multi-step aBLA pathway of the BPCIAâÂ?Â?s patent dispute resolution system, choosing instead to notify AMGEN of the aBLA filing, expected approval date, and intended launch. Instead of the BCPIAâÂ?Â?s elaborate process for confidential information exchange and resolution of patent disputes, SANDOZ opted out of the process and did not provide AMGEN with its aBLA application. Because SANDOZ failed to provide its application and manufacturing process, AMGEN was entitled to sue SANDOZ for patent infringement under non-compliance sanctions provided in BCPIA steps. AMGEN sued SANDOZ for unfair competition; conversion; and infringement of AMGENâÂ?Â?s patents. The, District Court dismissed unfair competition and conversion clams due to its interpretation of BPCIA, finding SANDOZ did not act unlawfully. On appeal to the Federal Circuit, the BCPIA was again interpreted in Amgen v. Sandoz, decided July 21, 2015. The Court reviewed SANDOZâÂ?Â?s failure to comply with the first step: applicant âÂ?Â?shall provideâÂ? its application and manufacturing process; 180 day notice of intent to market; and whether BCPIA steps are optional or mandatory. The Court found the BCPIA steps to be required when the aBLA path is chosen, but not when the applicant chooses not to use the BCPIA. Federal Circuit en banc review was requested.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Commentary · 30 Jul 2022
The Interpretation of Directors Duties during Administration and Liquidation of Company by the English Courts
Research article · 3 Feb 2022
The Interpretative Competence in Accordance with the Jordanian Constitutional Court Judiciary
Research article · 1 Jul 2021
Indonesian Constitutional Interpretation: Constitutional Court Versus the People's Consultative Assembly
Conference abstract · 30 Aug 2022
U.S. Biosimilars Market - A Deep Dive
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Denise M Kettelberger”

